Complement C3 (C3) Sheep Polyclonal Antibody
CAT#: BP370
Complement C3 (C3) sheep polyclonal antibody, Ig Fraction
Need it in bulk or conjugated?
Get a free quote
CNY 6,677.00
货期*
4周
规格
Product images
Specifications
Product Data | |
Applications | ELISA, ID |
Recommend Dilution | ELISA. Radial Immunodiffusion. |
Reactivity | Human |
Host | Sheep |
Clonality | Polyclonal |
Immunogen | Purified C3d from pooled activated serum |
Specificity | This antibody is specific for human C3d and gave a single arc in the alpha region when tested by IEP against aged human plasma (C3d) and a contiuous double arc in the alpha and beta regions when tested against fresh human plasma (C3 and C3d). |
Formulation | Glycine buffered saline, containing 0.09 % Sodium Azide (NaN3), 0.09 % EACA, 0.01 % Benzamidine and 1 mM EDTA State: Ig Fraction State: Liquid Ig fraction |
Purification | Ion exchange chromatography |
Conjugation | Unconjugated |
Storage Condition | Store the antibody at -20 °C. Ship at 2 - 8 °C. Avoid repeated freezing and thawing. |
Gene Name | complement component 3 |
Database Link | |
Background | The complement factor C3 consists of an alpha and a beta chain. C3 is a central factor in the complement cascade. It is central to the alternative pathway that leads to the C3 convertase C3bBb. The classical mannose binding lectin activation pathway leads to the C3 convertase C4b2a. These convertases cleave C3 resulting in C3a and C3b. Further degradation leads to the formation of the alpha chain products C3d, C3g and C3c. C3 is an acute phase protein that is produced by a wide range of tissues, including renal epithelial cells and hepatocytes. |
Synonyms | CPAMD1, Complement component 3 |
Note | Identity was confirmed by double diffusion (ouchterlony) vs human plasma and a known anti-human C3d. |
Reference Data | |
Protein Families | Druggable Genome |
Protein Pathways | Complement and coagulation cascades, Systemic lupus erythematosus |
Documents
Product Manuals |
FAQs |
SDS |
Resources
抗体相关资料 |
其它Complement C3产品
Customer
Reviews
Loading...